Camilla V.  Simpson net worth and biography

Camilla Simpson Biography and Net Worth

Director of Spruce Biosciences
Camilla V. Simpson holds the position of President & Managing Member at Rare Strategic LLC.

She is also on the board of Spruce Biosciences, Inc., Aristea Therapeutics, Inc. and Dyve Biosciences, Inc.

In the past Ms. Simpson held the position of Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. and Vice President-Regulatory Affairs for Shire Pharmaceuticals, Inc.

Camilla V. Simpson received an undergraduate degree from Kingston University, an undergraduate degree from National University of Ireland Galway and a graduate degree from Birkbeck University of London.

What is Camilla V. Simpson's net worth?

The estimated net worth of Camilla V. Simpson is at least $251.20 as of May 20th, 2021. Ms. Simpson owns 334 shares of Spruce Biosciences stock worth more than $251 as of March 28th. This net worth evaluation does not reflect any other assets that Ms. Simpson may own. Learn More about Camilla V. Simpson's net worth.

How do I contact Camilla V. Simpson?

The corporate mailing address for Ms. Simpson and other Spruce Biosciences executives is , , . Spruce Biosciences can also be reached via phone at 415-655-4168 and via email at [email protected]. Learn More on Camilla V. Simpson's contact information.

Has Camilla V. Simpson been buying or selling shares of Spruce Biosciences?

Camilla V. Simpson has not been actively trading shares of Spruce Biosciences during the last quarter. Most recently, Camilla V. Simpson sold 334 shares of the business's stock in a transaction on Thursday, May 20th. The shares were sold at an average price of $15.29, for a transaction totalling $5,106.86. Following the completion of the sale, the director now directly owns 334 shares of the company's stock, valued at $5,106.86. Learn More on Camilla V. Simpson's trading history.

Are insiders buying or selling shares of Spruce Biosciences?

During the last twelve months, insiders at the sold shares 3 times. They sold a total of 3,114,315 shares worth more than $2,613,101.31. The most recent insider tranaction occured on March, 20th when Major Shareholder Holdings A/S Novo sold 359,979 shares worth more than $262,784.67. Insiders at Spruce Biosciences own 5.9% of the company. Learn More about insider trades at Spruce Biosciences.

Information on this page was last updated on 3/20/2024.

Camilla V. Simpson Insider Trading History at Spruce Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2021Sell334$15.29$5,106.86334View SEC Filing Icon  
4/30/2021Sell14,045$16.14$226,686.3014,045View SEC Filing Icon  
See Full Table

Camilla V. Simpson Buying and Selling Activity at Spruce Biosciences

This chart shows Camilla V Simpson's buying and selling at Spruce Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spruce Biosciences Company Overview

Spruce Biosciences logo
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.75
Low: $0.73
High: $0.77

50 Day Range

MA: $3.62
Low: $0.70
High: $5.49

2 Week Range

Now: $0.75
Low: $0.68
High: $5.95

Volume

376,110 shs

Average Volume

1,211,640 shs

Market Capitalization

$30.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.68